346 related articles for article (PubMed ID: 18226083)
1. Serious staphylococcal infections--cyclic lipopeptides: meeting new challenges.
Graninger W
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():1-2. PubMed ID: 18226083
[No Abstract] [Full Text] [Related]
2. Treatment of staphylococcal infections with cyclic lipopeptides.
Eisenstein BI
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():10-6. PubMed ID: 18226085
[TBL] [Abstract][Full Text] [Related]
3. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
Mathiesen L; Midtvedt T; Solberg CO
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
[TBL] [Abstract][Full Text] [Related]
4. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Daum RS
N Engl J Med; 2007 Jul; 357(4):380-90. PubMed ID: 17652653
[No Abstract] [Full Text] [Related]
5. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.
Eisenstein BI; Oleson FB; Baltz RH
Clin Infect Dis; 2010 Jan; 50 Suppl 1():S10-5. PubMed ID: 20067387
[TBL] [Abstract][Full Text] [Related]
6. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.
Quist SR; Fierlbeck G; Seaton RA; Loeffler J; Chaves RL
Int J Antimicrob Agents; 2012 Jan; 39(1):90-1. PubMed ID: 21982144
[No Abstract] [Full Text] [Related]
7. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.
Falcone M; Russo A; Pompeo ME; Vena A; Marruncheddu L; Ciccaglioni A; Grossi P; Mancini C; Novelli A; Stefani S; Venditti M
Int J Antimicrob Agents; 2012 Jan; 39(1):64-8. PubMed ID: 22047703
[TBL] [Abstract][Full Text] [Related]
8. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
9. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
Vikram HR; Havill NL; Koeth LM; Boyce JM
J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
[TBL] [Abstract][Full Text] [Related]
10. The role of vancomycin in the treatment paradigm.
Stevens DL
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S51-7. PubMed ID: 16323121
[TBL] [Abstract][Full Text] [Related]
11. The treatment triangle for staphylococcal infections.
Grayson ML
N Engl J Med; 2006 Aug; 355(7):724-7. PubMed ID: 16914709
[No Abstract] [Full Text] [Related]
12. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies.
Gallon O; Guillet-Caruba C; Lamy B; Laurent F; Doucet-Populaire F; Decousser JW;
Eur J Clin Microbiol Infect Dis; 2009 Oct; 28(10):1209-15. PubMed ID: 19499255
[TBL] [Abstract][Full Text] [Related]
14. Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
Widmer AF
Clin Infect Dis; 2008 Mar; 46(5):656-8. PubMed ID: 18225983
[No Abstract] [Full Text] [Related]
15. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Whitman TJ
Dis Mon; 2008 Dec; 54(12):780-6. PubMed ID: 18996280
[No Abstract] [Full Text] [Related]
16. Caution when reconsidering empiric antimicrobial therapy for methicillin-resistant Staphylococcus aureus skin and soft-tissue infections.
da Silva LV; Zavascki AP; de Souza MV; Marcadenti A
Am J Surg; 2008 Oct; 196(4):618-9. PubMed ID: 18809069
[No Abstract] [Full Text] [Related]
17. Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia.
Jacobson LM; Milstone AM; Zenilman J; Carroll KC; Arav-Boger R
Pediatr Infect Dis J; 2009 May; 28(5):445-7. PubMed ID: 19295462
[TBL] [Abstract][Full Text] [Related]
18. Variability among pediatric infectious diseases specialists in the treatment and prevention of methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Creech CB; Beekmann SE; Chen Y; Polgreen PM
Pediatr Infect Dis J; 2008 Mar; 27(3):270-2. PubMed ID: 18277924
[TBL] [Abstract][Full Text] [Related]
19. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
Skiest DJ
J Clin Microbiol; 2006 Feb; 44(2):655-6. PubMed ID: 16455939
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for complicated skin and skin-structure infections.
Mendoza N; Tyring SK
Expert Opin Emerg Drugs; 2010 Sep; 15(3):509-20. PubMed ID: 20557269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
